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Abstract: Results from our group showed benzyl salicylate to be a moderate inhibitor of the CD81-LEL–HCV-E2 inter-
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1. INTRODUCTION 
  Recently the World Health Organization (WHO) esti-
mated that 3% of the world’s population has been infected 
with the Hepatitis C Virus (HCV) [1]. Infection with HCV is 
the most common cause of chronic hepatitis with frequent 
progression to liver cirrhosis and its sequelae [2]. Inhibition 
of the Hepatitis C Virus E2 glycoprotein (HCV-E2) binding 
to the large extracellular loop (LEL) of the human cell sur-
face protein CD81, a member of the tetraspanin family, pre-
vents infection of human hepatocytes, the HCV principal 
target cells [3]. The aim of the present work was to prepare 
compounds which bind to CD81-LEL and therefore inhibit 
the CD81-LEL–HCV-E2 interaction. 
  This work was based on results recently achieved in our 
group [4]. Briefly, we found benzyl salicylate (Fig. 1) to 
inhibit the CD81-LEL–HCV-E2 interaction (25% at 50 M) 
as outcome of a virtual screening followed by biological 
testing. Several heterocy-clic-substituted benzoic acid am-
ides were synthesized and tested for their biological activity. 
Some of the prepared compounds showed inhibition of the 
CD81-LEL–HCV-E2 interaction. 
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Fig. (1). Benzyl salicylate. 
2. RESULTS AND DISCUSSION 
2.1. Structure Modification 
  Based on the docking pose of benzyl salicylate into the 
published x-ray structure of CD81-LEL (pdb code: 1IV5) 
[5], we assumed that an extension of the planar/aromatic ring  
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system could increase the affinity to our intended binding 
site within a superficial cleft formed by two alpha-helices in 
the CD81-LEL structure. In order to maximize more specific 
hydrogen-bonding and electrostatic interactions with the 
target protein, we decided to introduce heterocyclic ring sys-
tems and amino acid moieties in opposite positions of an 
aromatic core structure. The aim of this work was therefore 
to prepare compounds of the general structure given in Fig. 
(2) and to determine their inhibition of the CD81-LEL–
HCV-E2 interaction. 
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Fig. (2). General structure of the synthesized benzoic acid amides 
(Het = Heterocycle, Y = -H, -OH, AA = L-alanine ethyl ester, L-
phenylalanine ethyl ester, L-tryptophane methyl ester). 
2.2. Syntheses and Biological Testing 
  In the first step of the preparation, starting from commer-
cially available reagents, the bromo substituted aromatic 
heterocycles were coupled to the correspon-ding boronic 
acids with tetrakis(triphenylphosphine) palladium (0) as 
catalyst  via  a Suzuki coupling reaction (cf. Scheme 1) in 
satisfying yields. The synthesized heterocyclic substituted 
carboxylic acids 12-16 as well as the applied bromo substi-
tuted heterocycles and boronic acids are shown in Table 1. 
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Scheme 1. Reagents and conditions: (i) 10 ml EtOH + 15 ml 10% 
Na2CO3-solution, Pd(PPh3)4, O2-free, 90°C over night (Y = -H, -
OH). 22    The Open Medicinal Chemistry Journal, 2008, Volume 2  Holzer et al. 
  The desired amides 1-11 (Table 2) were obtained in the 
second step by connecting the benzoic acids 12-16 to L-
alanine ethyl ester, L-phenylalanine ethyl ester and L-
tryptophane methyl ester using N,N’-dicyclohexyl carbodi-
imide (DCC) as coupling agent for microwave-assisted amide 
formation (cf. Scheme 2). 
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Scheme 2. Reagents and conditions: (i) Dicyclohexyl carbodiimide, 
dimethoxyethane / dichloromethane (5/1), microwaves: 225 Watt, 
135°C, 5 bar, 10 minutes. Het = Heterocycle, AA = amino acid ester: 
L-alanine ethyl ester, L-phenylalanine ethyl ester, L-tryptophane 
methyl ester, Y = -H, -OH. 
  Before we decided to apply microwave-assisted amide 
syntheses, activation of the carboxylic acids by means of 
thionyl chloride followed by addition of the corresponding 
amino acid esters was tried. This did not lead to the desired 
compounds. 
 DCC  coupling  reaction under standard conditions was 
performed next leading to the desired amides in very poor 
yields. Therefore microwave-assisted DCC coupling reaction 
was tried to increase the yield of the desired products. This 
attempt finally led to the target compounds 1-11 in satisfying 
yields. 
  A medium throughput assay developed in our group [6] 
was used to test the prepared compounds 1-11 for their bio-
logical activity. This assay is based on the procedure of Pileri 
et al. [7] in which the inhibition of the interaction of the fluo-
rescence-labeled CD81 antibody JS81 with HUH7.5 cells 
caused by our compounds is determined by FACS. The syn-
thesized compounds 1-11 showed no increased inhibition con-
cerning the CD81-LEL–HCV-E2 interaction compared to the 
original hit compound benzyl salicylate. 
3. EXPERIMENTAL SECTION 
3.1. General Procedure for the Suzuki Coupling Reaction 
  The boronic acid (1 equivalent) and the bromo substituted 
heterocycle (1 equivalent) were added to a mixture of 10 mL 
ethanol and 15 mL sodium carbonate solution (10%). This 
solution was free from oxygen by evacuating and flushing 
with nitrogen several times. After addition of 4 mol% of 
tetrakis(triphenylphosphine)palladium (0) the mixture was 
stirred at 90°C over night. 
  The remaining solid was filtered off at that temperature. 
Subsequently half of the solvent was removed under vacuum. 
The product precipitated after acidifying to pH 2 using formic 
acid. It was filtered off and dried under high vacuum. 
3.2. General Procedure for the Formation of the Amides 
  The carboxylic acid was stirred with an equivalent amount 
of the amino acid ester and dicyclohexyl carbodiimide (1.2 
equivalent) in the microwave oven (225 Watt, 135°C, 5 bar, 
10 minutes) using dry dichloromethane (4 mL) as solvent. 
After filtration the solvent was removed. Purification of the 
crude product was performed with column chromatography. 
3.3. Biological Test 
  HUH7.5 cells (1*10
5) were incubated with 100 l of the 
potential inhibitor (50 M + 1% DMSO) in 96 transwell plates 
Table 1.  Suzuki Coupling Reactions of Heterocycles and Boronic Acids Leading to Heterocyclic Substituted Carboxylic Acids (12-16) 
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for 10 minutes at room temperature. Next 4 L of the fluores-
cence-labeled CD81 antibody JS81 and 21 L of phosphate 
buffered saline buffer (PBS) were added and kept at room 
temperature for 10 minutes. After appending 125 L of PBS 
the cell suspension was incubated in the dark for 5 hours fol-
lowed by FACS analysis. 
3.4. Chemistry 
  Solvents and reagents were used as received from com-
mercial distributors without further purification. Anhydrous 
reactions were conducted under a nitrogen atmosphere. Pro-
ton and carbon NMR spectra were recorded at a Bruker AM 
500. The proton NMR spectra were recorded at 500 MHz, 
the carbon NMR spectra at 125 MHz. Chemical shifts  are 
reported in ppm units. Molecular mass was determined by 
liquid chromatography – tandem mass spectrometry (LC-
MS/MS) using a TSQ Quantum from Thermo Finnigan 
equipped with an electro spray interface and connected to a 
Surveyor HPLC (Thermo Finnigan). Positive and negative 
ion mass spectra were recorded (mass range m/z 150–1500) 
in normal scan mode. Melting points were determined using 
a Stuart Scientific SMP3 melting point apparatus. IR meas-
urements were performed on a Bruker Vector 33 at a fre-
quency range from 4000-250 cm
-1. Wave numbers  are re-
ported in cm
-1. Flash chromatography using Merck silica gel 
35/40–63/70. Microwave assisted syntheses was performed 
using a CEM DISCOVER microwave oven. 
 ( S)-Ethyl 2-[4-(pyridin-3-yl)benzamide]propanoate 
(1). Yield 24%. mp 118 °C IR 3330, 2930, 2851, 2478, 1745, 
1606, 1479, 1437, 1210, 1170 
1H-NMR (CDCl3) 8.75–8.74 
(1 H, m), 8.52–51 (1 H, m), 7.90–7.88 (3 H, m), 7.60 (1 H, d, 
J = 8.51), 7.40–7.37 (1 H, m), 7.29–7.27 (1 H, m), 4.72–4.70 
(1 H, m), 4.21–4.17 (2 H, q, J = 7.25), 1.48 (3 H, d, J = 
7.25), 1.24 (3 H, t, J = 7.25) 
13C-NMR (CDCl3) 173.38, 
166.86, 148.53, 147.70, 140.75, 135.86, 134.97, 127.97, 
127.20, 123.95, 61.70, 33.70, 18.13, 14.00 LC/MS-MS 
299.11 (M+H
+). 
 ( S)-Ethyl 2-[4-(quinolin-3-yl)benzamido]propano-ate 
(2). Yield 29%. mp 142 °C IR 3356, 2985, 1742, 1638, 1532, 
1439, 1205, 1172 
1H-NMR (CDCl3) 9.35 (1 H, s), 8.81 (1 H, 
s), 8.25–8.20 (4 H, m), 8.14–8.09 (3 H, m), 7.99–7.94 (1 H, 
m), 7.85–7.80 (1 H, m), 4.84–4.77 (1 H, m), 4.42–4.38 (2 H, 
m), 1.72–1.69 (3 H, m), 1.47 (3 H, t, J = 7.25) 
13C-NMR 
(CDCl3) 174.42, 169.59, 150.22, 148.12, 141.95, 135.74, 
134.85, 131.46, 129.72, 129.59, 129.54, 129.27, 128.99, 
128.68, 128.45, 128.21, 62.41, 50.35, 17.28, 14.50 LC/MS-
MS 349.05 (M+H
+). 
Table 2.  Amino Acid Esters, Carboxylic Acids and the Corresponding ‘Combinatorial’ Target Compounds 1-11 
 
  Amino Acid Ester 
Carboxylic Acids 
COOEt
NH2  
COOEt
NH2
Ph
 
COOMe
NH2 HN  
S
COOH
 
12 
 
 
O
HN
COOEt
S
Ph
 
5 
 
N
COOH
 
13 
N
O
HN
COOEt  
1 
O
HN
COOEt
Ph
N
 
6 
O
HN
COOMe
N
NH
 
10 
COOH
N  
14 
N
O
N
H
COOEt
 
2 
N
N
H
COOEt
Ph
O
 
7 
 
OH
COOH
N  
15 
N
OH
NH
O COOEt
 
3 
N
OH
NH
O COOEt
Ph
 
8 
 
N
N
COOH
 
16 
N
N
O
HN
COOEt 
5 
N
N
O
HN
COOEt
Ph
 
9 
N
N
O
HN
COOMe
NH
 
11 24    The Open Medicinal Chemistry Journal, 2008, Volume 2  Holzer et al. 
 ( S)-Ethyl 2-[4-hydroxy-3-(pyridin-3-yl)benzamide] 
propanoate (3). Yield 14%. IR 2926, 1738, 1642, 1541, 
1472, 1376, 1294, 1205 
1H-NMR (CDCl3) 9.01 (1 H, s), 
8.67–8.66 (1 H, m), 8.40–8.39 (1 H, m), 8.29–8.27 (1 H, m), 
7.91 (1 H, dd, J = 8.51), 7.84–7.80 (1 H, m), 7.70–7.67 (1 H, 
m), 7.24 (1 H, d, J = 8.51), 4.85–4.81 (1 H, m), 4.41–4.39 (2 
H, m), 1.71 (3 H, d, J = 7.25), 1.45 (3 H, t, J = 7.25) 
13C-
NMR (CDCl3) 174.31, 170.15, 161.51, 148.31, 147.98, 
136.00, 133.44, 133.05, 129.48, 128.15, 125.43, 119.49, 
117.49, 62.49, 50.02, 17.48, 14.47 LC/MS-MS 314.97 
(M+H
+). 
 ( S)-Ethyl 2-[4-(pyrimidin-5-yl)benzamido]propano-
ate (4). Yield 44%. mp 124 °C IR 2930, 2475, 1741, 1625, 
1550, 1415, 1213, 1161 
1H-NMR (d4-MeOH) 9.35 (1 H, s), 
9.30 (2 H, s), 8.22 (2 H, d, J = 8.55), 8.02 (2 H, d, J = 8.56), 
4.82–4.78 (1 H, m), 4.42–4.37 (2 H, m), 1.71 (3 H, d, J = 
7.57), 1.46 (3 H, t, J = 7.25) 
13C-NMR (d4-MeOH) 174.35, 
169.36, 158.47, 156.30, 138.54, 135.71, 135.06, 129.66, 
128.28, 62.41, 50.34, 17.25, 14.50 LC/MS-MS 300.02 
(M+H
+). 
 ( S)-Ethyl 3-phenyl-2-[4-(thiophen-3-yl)benzamido] 
propanoate (5). Yield 43%. mp 160 °C IR 3345, 2997, 
1748, 1634, 1517, 1178 
1H-NMR (CDCl3) 7.76 (2 H, d, J = 
8.51), 7.64 (2 H, d, J = 8.51), 7.54–7.53 (1 H, m), 7.42–7.41 
(2 H, m), 7.31–7.25 (3 H, m), 7.17–7.15 (2 H, m), 5.11–5.07 
(1 H, m), 4.23 (2 H, q, J = 6.94), 3.32–3.23 (2 H, m), 1.28 (3 
H, t, J = 7.25) 
13C-NMR (CDCl3) 171.66, 166.38, 141.16, 
139.07, 135.94, 132.32, 129.45, 128.58, 127.65, 127.14, 
126.67, 126.47, 126.16, 121.61, 61.67, 53.56, 37.99, 14.17 
LC/MS-MS 380.00 (M+H
+). 
 ( S)-Ethyl 3-phenyl-2-[4-(pyridin-3-yl)benzamido] 
propanoate (6). Yield 11%. mp 170 °C IR 3331, 2929, 
1735, 1628, 1537, 1311, 1197 
1H-NMR (CDCl3) 8.86 (1 H, 
s), 8.64–8.63 (1 H, m), 7.90–7.88 (1 H, m), 7.84 (2 H, d, J = 
8.51), 7.64 (2 H, d, J = 8.51), 7.40–7.39 (1 H, m), 7.32–7.30 
(2 H, m), 7.19–7.15 (3 H, m), 6.66–6.64 (1 H, m), 5.30 (2 H, 
s), 5.11–5.07 (1 H, m), 4.25–4.21 (2 H, m), 1.31–1.28 (3 H, 
m) LC/MS-MS 375.10 (M+H
+). 
 ( S)-Ethyl 3-phenyl-2-[4-(quinolin-3-yl)benzamido] 
propanoate (7). Yield 35%. mp 77 °C IR 3324, 2929, 2851, 
1741, 1626, 1572, 1529, 1208 
1H-NMR (CDCl3) 9.18 (1 H, 
s), 8.34–8.33 (1 H, m), 8.16–8.14 (1 H, d, J = 8.51), 7.91–
7.88 (3 H, m), 7.79–7.73 (3 H, m), 7.61–7.59 (1 H, m), 7.32–
7.28 (3 H, m), 7.18–7.17 (2 H, m), 6.71–6.69 (1 H, m), 5.12–
5.09 (1 H, m), 4.25 (2 H, q, J = 6.94), 3.36–3.25 (2 H, m), 
1.29 (3 H, t, J = 7.25) 
13C-NMR (CDCl3) 171.61, 166.25, 
149.50, 147.77, 135.89, 133.66, 133.45, 132.66, 129.86, 
129.44, 129.31, 128.61, 128.12, 127.94, 127.59, 127.21, 
61.73, 53.62, 25.63, 14.16 LC/MS-MS 425.13 (M+H
+). 
 ( S)-Ethyl 2-[2-hydroxy-5-(pyridin-3-yl)benzamido]-3-
phenylpropanoate (8). Yield 16%. mp 176 °C IR 3325, 
2928, 2851, 1744, 1625, 1572, 1244 
1H-NMR (CDCl3) 12.04 
(1 H, s), 8.67 (1 H, s), 8.51–8.50 (1 H, m), 7.71–7.70 (1 H, 
m), 7.55–7.53 (1 H, dd, J1 = 8.83, J2 = 2.19), 7.41–7.40 (1 H, 
m), 7.30–7.27 (1 H, m), 7.25–7.21 (3 H, m), 7.11–7.09 (2 H, 
m), 7.02 (1 H, d, J = 8.83), 6.97 (1 H, d, J = 7.25), 4.98–4.94 
(1 H, m), 4.17 (2 H, q, J = 7.25), 3.25–3.17 (2 H, m), 1.22 (3 
H, t, J = 7.25) 
13C-NMR (CDCl3) 171.33, 169.11, 148.26, 
147.82, 135.55, 133.97, 133.19, 129.35, 128.72, 127.43, 
119.41, 114.56, 61.96, 33.95, 24.94, 14.14 LC/MS-MS 
391.05 (M+H
+). 
 ( S)-Ethyl 3-phenyl-2-[4-(pyrimidin-5-yl)benzami-
do]propanoate (9). Yield 32%. mp 129 °C IR 3269, 2928, 
1738, 1652, 1530, 1414, 1349, 1192 
1H-NMR (CDCl3) 9.24 
(1 H, s), 8.97 (2 H, s), 7.88 (2 H, d, J = 8.51), 7.65 (2 H, d, J 
= 8.51), 7.32 (3 H, m), 7.16–7.14 (2 H, m), 6.67–6.66 (1 H, 
m), 5.10–5.07 (1 H, m), 4.24 (2 H, q, J = 7.25), 3.34–3.24 (2 
H, m), 1.41 (3 H, t, J = 7.25) 
13C-NMR (CDCl3) 171.55, 
165.93, 158.06, 154.97, 137.55, 135.80, 134.42, 133.34, 
129.41, 128.62, 128.16, 127.24, 61.79, 53.62, 37.90, 14.17 
LC/MS-MS 376.08 (M+H
+). 
 ( S)-Methyl 3-(1H-indol-3-yl)-2-[4-(pyridin-3-yl) ben-
zamido]propanoate (10). Yield 24%. mp 96 °C IR 3266, 
1737, 1642, 1530, 1435, 1215 
1H-NMR (CDCl3) 8.75 (1 H, 
s), 8.55 (1 H, s), 8.40 (1 H, s), 7.80–7.77 (1 H, m), 7.70 (2 H, 
d, J = 8.51), 7.49 (3 H, s), 7.31–7.27 (2 H, m), 7.12–7.09 (1 
H, m), 7.03–7.00 (1 H, m), 6.95–6.94 (1 H, m), 6.70 (1 H, d, 
J = 7.57), 5.11–5.08 (1 H, m), 3.66 (3 H, s), 3.44–3.36 (2 H, 
m) 
13C-NMR (CDCl3) 172.38, 166.40, 149.09, 148.23, 
141.04, 136.21, 134.47, 133.40, 127.94, 127.71, 127.22, 
122.91, 122.31, 119.75, 118.63, 111.40, 109.95, 53.60, 
52.49, 27.64 LC/MS-MS 400.08 (M+H
+). 
 ( S)-Methyl 3-(1H-indol-3-yl)-2-[4-(pyrimidin-5-yl) 
benzamido]propanoate (11). Yield 14%. mp 101 °C IR 
3298, 1736, 1646, 1532, 1415, 1344, 1215 
1H-NMR (CDCl3) 
9.23 (1 H, s), 8.95 (2 H, s), 8.26 (1 H, s), 7.81 (2 H, d, J = 
8.20), 7.60–7.55 (3 H, m), 7.36 (1 H, d, J = 8.20), 7.21–7.18 
(1 H, m), 7.10–7.08 (1 H, m), 7.03–7.02 (1 H, m), 6.76 (1 H, 
d, J = 7.57), 5.20–5.16 (1 H, m), 3.76 (3 H, s), 3.53–3.47 (2 
H, m) 
13C-NMR (CDCl3) 172.31, 166.11, 157.87, 154.94, 
137.37, 136.16, 134.32, 133.38, 128.27, 127.71, 127.12, 
127.00, 122.82, 122.41, 119.83, 118.62, 111.38, 109.99, 
53.65, 52.55, 27.59 LC/MS-MS 400.98 (M+H
+). 
  4-(Thiophen-3-yl)benzoic acid (12). Yield 94%. mp 280 
°C (Lit. 281-282 °C) [8] 
1H-NMR (d6-DMSO) 8.05–8.04 (1 
H, m), 7.96 (2 H, d, J = 8.51), 7.85 (2 H, d, J = 8.20), 7.63–
7.68 (1 H, m), 7.64–7.63 (1 H, m). 
13C-NMR (d6-DMSO): 
167.02, 140.31, 139.09, 129.92, 129.07, 127.46, 126.14, 
125.99, 122.79. 
  4-(Pyridin-3-yl)benzoic acid (13). Yield 62%. mp 215 
°C (Lit. 215 °C) [9] 
1H-NMR (D2O/TFA) 7.80 (1 H, s), 
7.61–7.56 (2 H, m), 7.00 (2 H, d, J = 8.51), 6.96–6.93 (1 H, 
m), 6.56 (2 H, d, J = 8.51) 
13C-NMR was not applied due to 
the TFA. 
  4-(Chinolin-3-yl)benzoic acid (14). Yield 92%. 
1H-
NMR (d6-DMSO/TFA: 1/1) 9.66 (1 H, s), 9.51 (1 H, s), 
7.80–7.78 (1 H, m), 8.38 (1 H, d, J = 7.88), 8.27 (1 H, d, J = 
8.51), 8.15–8.08 (5 H, m), 7.98–7.95 (1 H, m) [Lit. 250 
MHz, d6-DMSO: 13.09 (1 H, br s), 9.32 (1 H, d), 8.76 (1 H, 
d), 8.07 (5 H, m), 7.83 (2 H, m), 7.67 (1 H, m)] [10] 
13C-
NMR (d6-DMSO + TFA) 166.79, 144.39, 132.64, 131.15, 
130.18, 127.61, 129.76, 129.47, 118.44, 116.15, 113.85, 
111.56. 
  5-(Pyridin-3-yl)salicylic acid (15). Yield 46%. mp 260 
°C (Lit. 263 °C) [11] 
1H-NMR (D2O/TFA: 1/1) 7.61 (1 H, s), 
7.42–7.40 (1 H, m), 7.36–7.35 (1 H, m), 6.93 (1 H, d, J = 
2.52), 6.78–6.75 (1 H, m), 6.49 (1 H, dd, J = 8.51), 5.84 (1 
H, d, J = 8.83) 
13C-NMR was not applied due to the TFA. Microwave-Assisted Syntheses of Potential HCV Antivirals  The Open Medicinal Chemistry Journal, 2008, Volume 2    25 
  4-(Pyrimidin-5-yl)benzoic acid (16). Yield 60%. mp 
218 °C (Lit. 220 °C) [12] 
1H-NMR (d6-DMSO) 9.17 (1 H, s), 
9.15 (2 H, s), 8.01 (2 H, d, J = 8.20), 7.74 (2 H, d, J = 8.20) 
13C-NMR (d6-DMSO) 169.60, 157.11, 154.60, 140.35, 
133.92, 133.18, 131.47, 131.39, 129.85, 128.75, 125.81. 
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